Brain signalling systems: A target for treating type I diabetes mellitus

Area of Science:

• Neuroscience
• Endocrinology
• Biochemistry

Background:

• Type I Diabetes Mellitus (TIDM) significantly alters brain signaling molecules, including indolamines and protein kinases, contributing to metabolic disorders and systemic complications.
• While the effects of diabetes on these signaling systems are recognized, the precise pathophysiological mechanisms remain incompletely understood, with hyperglycemia, acidosis, and insulin resistance playing likely roles.

Purpose of the Study:

• To review the mechanisms of protein kinases, CaM Kinase, and serotonin transporter-mediated alterations of indolamines in Type I Diabetes Mellitus (TIDM).
• To discuss how specific brain regions respond to insulin or pharmacological agents that modulate these signaling molecules for potential therapeutic applications in diabetic brain disorders.

Main Methods:

• Review of existing research on signaling molecule alterations in Type I Diabetes Mellitus (TIDM).
• Analysis of the role of insulin signaling, including receptor tyrosine kinase activity and substrate phosphorylation.
• Examination of the involvement of serine/threonine kinases and indolamines in diabetic pathophysiology.

Main Results:

• Significant alterations in brain indolamines and protein kinases are observed from early to later stages of TIDM.
• Insulin receptor activation leads to phosphorylation of substrates, creating binding sites for signaling molecules like kinases and indolamines.
• Research over two decades has focused on protein kinases, CaM Kinase, and serotonin transporter mechanisms in TIDM.

Conclusions:

• Understanding the complex signaling pathways affected by TIDM is crucial for addressing metabolic disorders and systemic impairments.
• Investigating regional brain responses to insulin and therapeutic agents offers potential avenues for treating specific diabetic brain complications.